查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1487541

孤兒藥市場 - 2024-2034 年全球產業分析、規模、佔有率、成長、趨勢與預測

Orphan Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 199 Pages | 商品交期: 2-10個工作天內

價格

孤兒藥市場 - 報告範圍

TMR 關於全球孤兒藥市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2024 年至 2034 年預測期內市場指標的寶貴見解。 ，考慮2024年為基準年，2034年為預測年。報告也提供了2024年至2034年全球孤兒藥市場的年複合成長率（CAGR%）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解孤兒藥市場。

市場概況
2023年市場價值 1,950 億美元
2034 年市場價值 4240 億美元
複合年成長率 6.9%

該報告深入探討了全球孤兒藥市場的競爭格局。全球孤兒藥市場的主要參與者已被確定，並且每一位參與者都已根據各種屬性進行了分析。公司概況、財務狀況、近期發展和 SWOT 是本報告中介紹的全球孤兒藥市場參與者的屬性。

目錄

第1章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概述

  • 介紹
  • 概述
  • 市場動態
  • 2020-2034年全球市場分析與預測

第 5 章：關鍵見解

  • 管道分析
  • 主要產品/品牌分析
  • 主要併購
  • COVID-19 大流行對該行業的影響

第 6 章：全球市場分析與預測：依疾病類型

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依疾病類型，2020-2034
    • 腫瘤學
    • 胃腸道
    • 肺部
    • 神經病學
    • 血液學
    • 心血管
    • 代謝紊亂
    • 內分泌科
    • 傳染性疾病
    • 其他
  • 市場吸引力：按疾病類型

第 7 章：全球市場分析與預測：依指標

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依指標，2020-2034
    • 生物製劑
    • 非生物的
  • 市場吸引力：按指標

第 8 章：全球市場分析與預測：按配銷通路

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：按配銷通路，2020-2034
    • 醫院藥房
    • 專業藥房
    • 零售藥局
    • 其他
  • 市場吸引力：按配銷通路分類

第 9 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2020-2034
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力：按地區

第 10 章：北美市場分析與預測

第 11 章：歐洲市場分析與預測

第 12 章：亞太市場分析與預測

第 13 章：拉丁美洲市場分析與預測

第 14 章：中東和非洲市場分析與預測

第15章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2023）
  • 公司簡介
    • Novartis AG
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • F. Hoffmann-La Roche Ltd.
    • Pfizer, Inc.
    • Sanofi SA
    • Alexion Pharmaceuticals, Inc.
    • Eli Lilly and Company
    • Novo Nordisk A/S
    • AstraZeneca plc
    • Eisai Co., Ltd.
    • Daiichi Sankyo Company Limited
    • Bayer AG
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Johnson & Johnson
    • Biogen, Inc.
    • Shire plc
    • Amgen, Inc.
Product Code: TMRGL1254

Orphan Drugs Market - Scope of Report

TMR's report on the global orphan drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global orphan drugs market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global orphan drugs market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the orphan drugs market.

Market Snapshot
Market Value in 2023US$ 195 Bn
Market Value in 2034US$ 424 Bn
CAGR6.9%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global orphan drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global orphan drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global orphan drugs market.

The report delves into the competitive landscape of the global orphan drugs market. Key players operating in the global orphan drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global orphan drugs market profiled in this report.

Key Questions Answered in Global orphan drugs Market Report:

  • What is the sales/revenue generated by orphan drugs across all regions during the forecast period?
  • What are the opportunities in the global orphan drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Orphan Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global orphan drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global orphan drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global orphan drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Orphan Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Orphan Drugs Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Orphan Drugs Market Analysis and Forecast, by Disease Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Disease Type, 2020-2034
    • 6.3.1. Oncology
    • 6.3.2. Gastrointestinal
    • 6.3.3. Pulmonary
    • 6.3.4. Neurology
    • 6.3.5. Hematology
    • 6.3.6. Cardiovascular
    • 6.3.7. Metabolic Disorders
    • 6.3.8. Endocrinology
    • 6.3.9. Infectious Diseases
    • 6.3.10. Others
  • 6.4. Market Attractiveness, by Disease Type

7. Global Orphan Drugs Market Analysis and Forecast, by Indicator

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Indicator, 2020-2034
    • 7.3.1. Biologic
    • 7.3.2. Non-biologic
  • 7.4. Market Attractiveness, by Indicator

8. Global Orphan Drugs Market Analysis and Forecast, By Distribution Channel

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, By Distribution Channel, 2020-2034
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Specialty Pharmacies
    • 8.3.3. Retail Pharmacies
    • 8.3.4. Others
  • 8.4. Market Attractiveness, By Distribution Channel

9. Global Orphan Drugs Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness, by Region

10. North America Orphan Drugs Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Disease Type, 2020-2034
    • 10.2.1. Oncology
    • 10.2.2. Gastrointestinal
    • 10.2.3. Pulmonary
    • 10.2.4. Neurology
    • 10.2.5. Hematology
    • 10.2.6. Cardiovascular
    • 10.2.7. Metabolic Disorders
    • 10.2.8. Endocrinology
    • 10.2.9. Infectious Diseases
    • 10.2.10. Others
  • 10.3. Market Attractiveness, by Disease Type
  • 10.4. Market Value Forecast, by Indicator, 2020-2034
    • 10.4.1. Biologic
    • 10.4.2. Non-biologic
  • 10.5. Market Attractiveness, by Indicator
  • 10.6. Market Value Forecast, By Distribution Channel, 2020-2034
    • 10.6.1. Hospital Pharmacies
    • 10.6.2. Specialty Pharmacies
    • 10.6.3. Retail Pharmacies
    • 10.6.4. Others
  • 10.7. Market Attractiveness, By Distribution Channel
  • 10.8. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 10.8.1. U.S.
    • 10.8.2. Canada
  • 10.9. Market Attractiveness Analysis
    • 10.9.1. By Disease Type
    • 10.9.2. By Indicator
    • 10.9.3. By Distribution Channel
    • 10.9.4. By Country

11. Europe Orphan Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Disease Type, 2020-2034
    • 11.2.1. Oncology
    • 11.2.2. Gastrointestinal
    • 11.2.3. Pulmonary
    • 11.2.4. Neurology
    • 11.2.5. Hematology
    • 11.2.6. Cardiovascular
    • 11.2.7. Metabolic Disorders
    • 11.2.8. Endocrinology
    • 11.2.9. Infectious Diseases
    • 11.2.10. Others
  • 11.3. Market Attractiveness, by Disease Type
  • 11.4. Market Value Forecast, by Indicator, 2020-2034
    • 11.4.1. Biologic
    • 11.4.2. Non-biologic
  • 11.5. Market Attractiveness, by Indicator
  • 11.6. Market Value Forecast, By Distribution Channel, 2020-2034
    • 11.6.1. Hospital Pharmacies
    • 11.6.2. Specialty Pharmacies
    • 11.6.3. Retail Pharmacies
    • 11.6.4. Others
  • 11.7. Market Attractiveness, By Distribution Channel
  • 11.8. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.8.1. Germany
    • 11.8.2. U.K.
    • 11.8.3. France
    • 11.8.4. Italy
    • 11.8.5. Spain
    • 11.8.6. Rest of Europe
  • 11.9. Market Attractiveness Analysis
    • 11.9.1. By Disease Type
    • 11.9.2. By Indicator
    • 11.9.3. By Distribution Channel
    • 11.9.4. By Country/Sub-region

12. Asia Pacific Orphan Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Disease Type, 2020-2034
    • 12.2.1. Oncology
    • 12.2.2. Gastrointestinal
    • 12.2.3. Pulmonary
    • 12.2.4. Neurology
    • 12.2.5. Hematology
    • 12.2.6. Cardiovascular
    • 12.2.7. Metabolic Disorders
    • 12.2.8. Endocrinology
    • 12.2.9. Infectious Diseases
    • 12.2.10. Others
  • 12.3. Market Attractiveness, by Disease Type
  • 12.4. Market Value Forecast, by Indicator, 2020-2034
    • 12.4.1. Biologic
    • 12.4.2. Non-biologic
  • 12.5. Market Attractiveness, by Indicator
  • 12.6. Market Value Forecast, By Distribution Channel, 2020-2034
    • 12.6.1. Hospital Pharmacies
    • 12.6.2. Specialty Pharmacies
    • 12.6.3. Retail Pharmacies
    • 12.6.4. Others
  • 12.7. Market Attractiveness, By Distribution Channel
  • 12.8. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.8.1. China
    • 12.8.2. Japan
    • 12.8.3. India
    • 12.8.4. Australia & New Zealand
    • 12.8.5. Rest of Asia Pacific
  • 12.9. Market Attractiveness Analysis
    • 12.9.1. By Disease Type
    • 12.9.2. By Indicator
    • 12.9.3. By Distribution Channel
    • 12.9.4. By Country/Sub-region

13. Latin America Orphan Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Disease Type, 2020-2034
    • 13.2.1. Oncology
    • 13.2.2. Gastrointestinal
    • 13.2.3. Pulmonary
    • 13.2.4. Neurology
    • 13.2.5. Hematology
    • 13.2.6. Cardiovascular
    • 13.2.7. Metabolic Disorders
    • 13.2.8. Endocrinology
    • 13.2.9. Infectious Diseases
    • 13.2.10. Others
  • 13.3. Market Attractiveness, by Disease Type
  • 13.4. Market Value Forecast, by Indicator, 2020-2034
    • 13.4.1. Biologic
    • 13.4.2. Non-biologic
  • 13.5. Market Attractiveness, by Indicator
  • 13.6. Market Value Forecast, By Distribution Channel, 2020-2034
    • 13.6.1. Hospital Pharmacies
    • 13.6.2. Specialty Pharmacies
    • 13.6.3. Retail Pharmacies
    • 13.6.4. Others
  • 13.7. Market Attractiveness, By Distribution Channel
  • 13.8. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.8.1. Brazil
    • 13.8.2. Mexico
    • 13.8.3. Rest of Latin America
  • 13.9. Market Attractiveness Analysis
    • 13.9.1. By Disease Type
    • 13.9.2. By Indicator
    • 13.9.3. By Distribution Channel
    • 13.9.4. By Country/Sub-region

14. Middle East & Africa Orphan Drugs Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Disease Type, 2020-2034
    • 14.2.1. Oncology
    • 14.2.2. Gastrointestinal
    • 14.2.3. Pulmonary
    • 14.2.4. Neurology
    • 14.2.5. Hematology
    • 14.2.6. Cardiovascular
    • 14.2.7. Metabolic Disorders
    • 14.2.8. Endocrinology
    • 14.2.9. Infectious Diseases
    • 14.2.10. Others
  • 14.3. Market Attractiveness, by Disease Type
  • 14.4. Market Value Forecast, by Indicator, 2020-2034
    • 14.4.1. Biologic
    • 14.4.2. Non-biologic
  • 14.5. Market Attractiveness, by Indicator
  • 14.6. Market Value Forecast, By Distribution Channel, 2020-2034
    • 14.6.1. Hospital Pharmacies
    • 14.6.2. Specialty Pharmacies
    • 14.6.3. Retail Pharmacies
    • 14.6.4. Others
  • 14.7. Market Attractiveness, By Distribution Channel
  • 14.8. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.8.1. GCC Countries
    • 14.8.2. South Africa
    • 14.8.3. Rest of Middle East & Africa
  • 14.9. Market Attractiveness Analysis
    • 14.9.1. By Disease Type
    • 14.9.2. By Indicator
    • 14.9.3. By Distribution Channel
    • 14.9.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. Novartis AG
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Bristol-Myers Squibb Company
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Celgene Corporation
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. F. Hoffmann-La Roche Ltd.
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Pfizer, Inc.
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Sanofi S.A.
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Alexion Pharmaceuticals, Inc.
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Eli Lilly and Company
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Novo Nordisk A/S
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. SWOT Analysis
      • 15.3.9.5. Strategic Overview
    • 15.3.10. AstraZeneca plc
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. Financial Overview
      • 15.3.10.4. SWOT Analysis
      • 15.3.10.5. Strategic Overview
    • 15.3.11. Eisai Co., Ltd.
      • 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. Financial Overview
      • 15.3.11.4. SWOT Analysis
      • 15.3.11.5. Strategic Overview
    • 15.3.12. Daiichi Sankyo Company Limited
      • 15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.12.2. Product Portfolio
      • 15.3.12.3. Financial Overview
      • 15.3.12.4. SWOT Analysis
      • 15.3.12.5. Strategic Overview
    • 15.3.13. Bayer AG
      • 15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.13.2. Product Portfolio
      • 15.3.13.3. Financial Overview
      • 15.3.13.4. SWOT Analysis
      • 15.3.13.5. Strategic Overview
    • 15.3.14. GlaxoSmithKline plc
      • 15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.14.2. Product Portfolio
      • 15.3.14.3. Financial Overview
      • 15.3.14.4. SWOT Analysis
      • 15.3.14.5. Strategic Overview
    • 15.3.15. Merck & Co., Inc.
      • 15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.15.2. Product Portfolio
      • 15.3.15.3. Financial Overview
      • 15.3.15.4. SWOT Analysis
      • 15.3.15.5. Strategic Overview
    • 15.3.16. Johnson & Johnson
      • 15.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.16.2. Product Portfolio
      • 15.3.16.3. Financial Overview
      • 15.3.16.4. SWOT Analysis
      • 15.3.16.5. Strategic Overview
    • 15.3.17. Biogen, Inc.
      • 15.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.17.2. Product Portfolio
      • 15.3.17.3. Financial Overview
      • 15.3.17.4. SWOT Analysis
      • 15.3.17.5. Strategic Overview
    • 15.3.18. Shire plc
      • 15.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.18.2. Product Portfolio
      • 15.3.18.3. Financial Overview
      • 15.3.18.4. SWOT Analysis
      • 15.3.18.5. Strategic Overview
    • 15.3.19. Amgen, Inc.
      • 15.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.19.2. Product Portfolio
      • 15.3.19.3. Financial Overview
      • 15.3.19.4. SWOT Analysis
      • 15.3.19.5. Strategic Overview

List of Tables

  • Table 01: Global Orphan Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020-2034
  • Table 02: Global Orphan Drugs Market Size (US$ Mn) Forecast, by Indicator, 2020-2034
  • Table 03: Global Orphan Drugs Market Size (US$ Mn) Forecast, by Region, 2020-2034
  • Table 04: North America Orphan Drugs Market Size (US$ Mn) Forecast, by Country, 2020-2034
  • Table 05: North America Orphan Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020-2034
  • Table 06: North America Orphan Drugs Market Size (US$ Mn) Forecast, by Indicator, 2020-2034
  • Table 07: Europe Orphan Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 08: Europe Orphan Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020-2034
  • Table 09: Europe Orphan Drugs Market Size (US$ Mn) Forecast, by Indicator, 2020-2034
  • Table 10: Asia Pacific Orphan Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 11: Asia Pacific Orphan Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020-2034
  • Table 12: Asia Pacific Orphan Drugs Market Size (US$ Mn) Forecast, by Indicator, 2020-2034
  • Table 13: Latin America Orphan Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Latin America Orphan Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020-2034
  • Table 15: Latin America Orphan Drugs Market Size (US$ Mn) Forecast, by Indicator, 2020-2034
  • Table 16: Middle East & Africa Orphan Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 17: Middle East & Africa Orphan Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020-2034
  • Table 18: Middle East & Africa Orphan Drugs Market Size (US$ Mn) Forecast, by Indicator, 2020-2034

List of Figures

  • Figure 01: Global Orphan Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034
  • Figure 02: Global Orphan Drugs Market Revenue (US$ Mn), by Disease Type, 2023
  • Figure 03: Global Orphan Drugs Market Value Share, by Disease Type, 2023
  • Figure 04: Global Orphan Drugs Market Revenue (US$ Mn), by Indicator, 2023
  • Figure 05: Global Orphan Drugs Market Value Share, by Indicator, 2023
  • Figure 06: Global Orphan Drugs Market Revenue (US$ Mn), By Distribution Channel, 2023
  • Figure 07: Global Orphan Drugs Market Value Share, By Distribution Channel, 2023
  • Figure 08: Global Orphan Drugs Market Value Share, by Region, 2023
  • Figure 09: Global Orphan Drugs Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 10: Global Orphan Drugs Market Value Share Analysis, by Disease Type, 2023 and 2034
  • Figure 11: Global Orphan Drugs Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 12: Global Orphan Drugs Market Value Share Analysis, by Indicator, 2023 and 2034
  • Figure 13: Global Orphan Drugs Market Attractiveness Analysis, by Indicator, 2024-2034
  • Figure 14: Global Orphan Drugs Market Value Share Analysis, By Distribution Channel, 2023 and 2034
  • Figure 15: Global Orphan Drugs Market Attractiveness Analysis, By Distribution Channel, 2024-2034
  • Figure 16: Global Orphan Drugs Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 17: Global Orphan Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 18: North America Orphan Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 19: North America Orphan Drugs Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 20: North America Orphan Drugs Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 21: North America Orphan Drugs Market Value Share Analysis, by Disease Type, 2023 and 2034
  • Figure 22: North America Orphan Drugs Market Value Share Analysis, by Indicator, 2023 and 2034
  • Figure 23: North America Orphan Drugs Market Value Share Analysis, By Distribution Channel, 2023 and 2034
  • Figure 24: North America Orphan Drugs Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 25: North America Orphan Drugs Market Attractiveness Analysis, by Indicator, 2024-2034
  • Figure 26: Europe Orphan Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 27: Europe Orphan Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 28: Europe Orphan Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 29: Europe Orphan Drugs Market Value Share Analysis, by Disease Type, 2023 and 2034
  • Figure 30: Europe Orphan Drugs Market Value Share Analysis, by Indicator, 2023 and 2034
  • Figure 31: Europe Orphan Drugs Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 32: Europe Orphan Drugs Market Attractiveness Analysis, by Indicator, 2024-2034
  • Figure 33: Europe Orphan Drugs Market Attractiveness Analysis, By Distribution Channel, 2024-2034
  • Figure 34: Asia Pacific Orphan Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 35: Asia Pacific Orphan Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 36: Asia Pacific Orphan Drugs Market Value Share Analysis, by Disease Type, 2023 and 2034
  • Figure 37: Asia Pacific Orphan Drugs Market Value Share Analysis, by Indicator, 2023 and 2034
  • Figure 38: Asia Pacific Orphan Drugs Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 39: Asia Pacific Orphan Drugs Market Attractiveness Analysis, by Indicator, 2024-2034
  • Figure 40: Latin America Orphan Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 41: Latin America Orphan Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 42: Latin America Orphan Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 43: Latin America Orphan Drugs Market Value Share Analysis, by Disease Type, 2023 and 2034
  • Figure 44: Latin America Orphan Drugs Market Value Share Analysis, by Indicator, 2023 and 2034
  • Figure 45: Latin America Orphan Drugs Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 46: Latin America Orphan Drugs Market Attractiveness Analysis, by Indicator, 2024-2034
  • Figure 47: Middle East & Africa Orphan Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 48: Middle East & Africa Orphan Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 49: Middle East & Africa Orphan Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 50: Middle East & Africa Orphan Drugs Market Value Share Analysis, by Disease Type, 2023 and 2034
  • Figure 51: Middle East & Africa Orphan Drugs Market Value Share Analysis, by Indicator, 2023 and 2034
  • Figure 52: Middle East & Africa Orphan Drugs Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 53: Middle East & Africa Orphan Drugs Market Attractiveness Analysis, by Indicator, 2024-2034